New Delhi, Sept. 15 -- Shares of Sudarshan Pharma Industries are likely to attract investors' interest on Wednesday, September 16, after the company said the proposal to acquire a 9.50% equity stake in MedTherapy Biotechnology Inc., USA, remains under due diligence, while confirmation and a board resolution from MedTherapy are also pending.

The company added that the proposed acquisition of a 1.50% stake each by its promoters, Hemal Mehta, Chairman & Managing Director, and Sachin Mehta, Joint Managing Director, is also under due diligence, with the MedTherapy board's confirmation and resolution pending. The company said it will provide an update at the earliest.

The update comes after the company said in an exchange filing on September ...